Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Achim Aigner

Showing results (51-60 of 174) with videos related to

Pageof 18
Sort By:
Bioconjugate Chemistry|July 22, 2004
Physicochemical and biological characterization of polyethylenimine-graft-poly(ethylene glycol) block copolymers as a delivery system for oligonucleotides and ribozymesCarola Brus, Holger Petersen, Achim Aigner, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 20, 2004
Efficiency of polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradationCarola Brus, Holger Petersen, Achim Aigner, et al.
BMC Cancer|January 5, 2017
Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cellsAnja Frömberg, Michael Rabe, Henry Oppermann, et al.
The Journal of Biological Chemistry|January 26, 2002
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growthCiaran Powers, Achim Aigner, Gerald E Stoica, et al.
Nucleic Acid Therapeutics|June 4, 2013
U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastomaUlrike Weirauch, Arnold Grünweller, Luis Cuellar, et al.
Pharmaceuticals (Basel, Switzerland)|October 11, 2016
Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in GlioblastomaSabrina Höbel, Chantal C M Appeldoorn, Pieter J Gaillard, et al.
International Journal of Oncology|January 3, 2020
Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progressionPia Kronschnabl, Arnold Grünweller, Roland K Hartmann, et al.
Scientific Reports|October 31, 2019
Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effectsHannes Borchardt, Alexander Schulz, Kaustubh Datta, et al.
Cancers|February 10, 2021
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future PerspectivesRobert Jenke, Nina Reßing, Finn K Hansen, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|November 25, 2010
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lungMelanie Günther, Jens Lipka, Anastasia Malek, et al.
Pageof 18

Showing results (51-60 of 174) with videos related to

Sort By:
Pageof 18
Bioconjugate Chemistry|July 22, 2004
Physicochemical and biological characterization of polyethylenimine-graft-poly(ethylene glycol) block copolymers as a delivery system for oligonucleotides and ribozymesCarola Brus, Holger Petersen, Achim Aigner, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|April 20, 2004
Efficiency of polyethylenimines and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect oligonucleotides against enzymatic degradationCarola Brus, Holger Petersen, Achim Aigner, et al.
BMC Cancer|January 5, 2017
Analysis of cellular and molecular antitumor effects upon inhibition of SATB1 in glioblastoma cellsAnja Frömberg, Michael Rabe, Henry Oppermann, et al.
The Journal of Biological Chemistry|January 26, 2002
Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growthCiaran Powers, Achim Aigner, Gerald E Stoica, et al.
Nucleic Acid Therapeutics|June 4, 2013
U1 adaptors for the therapeutic knockdown of the oncogene pim-1 kinase in glioblastomaUlrike Weirauch, Arnold Grünweller, Luis Cuellar, et al.
Pharmaceuticals (Basel, Switzerland)|October 11, 2016
Targeted CRM197-PEG-PEI/siRNA Complexes for Therapeutic RNAi in GlioblastomaSabrina Höbel, Chantal C M Appeldoorn, Pieter J Gaillard, et al.
International Journal of Oncology|January 3, 2020
Inhibition of PIM2 in liver cancer decreases tumor cell proliferation in vitro and in vivo primarily through the modulation of cell cycle progressionPia Kronschnabl, Arnold Grünweller, Roland K Hartmann, et al.
Scientific Reports|October 31, 2019
Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effectsHannes Borchardt, Alexander Schulz, Kaustubh Datta, et al.
Cancers|February 10, 2021
Anticancer Therapy with HDAC Inhibitors: Mechanism-Based Combination Strategies and Future PerspectivesRobert Jenke, Nina Reßing, Finn K Hansen, et al.
European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V|November 25, 2010
Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lungMelanie Günther, Jens Lipka, Anastasia Malek, et al.
Pageof 18